Clinical Trial Update: Safety Study of SGN-CD70A in Cancer Patients [Phase 1]

View source ↗

Summary

A Phase 1 safety study of SGN-CD70A in renal cell carcinoma and several lymphomas has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Renal Cell Carcinoma

Drugs mentioned

• SGN-CD70A

Snippet

Sponsor: Seagen Inc. | Conditions: Renal Cell Carcinoma, Mantle-Cell Lymphoma | Phase 1 | Status: COMPLETED